A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

PHASE3CompletedINTERVENTIONAL

Enrollment

366

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

January 25, 2022

Study Completion Date

January 25, 2022

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG

Aflibercept

Intravitreal (IVT) injection

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05345236 - A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) | Biotech Hunter | Biotech Hunter